Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Physiopathology of Behavioral Addictions and Biomarkers (MiRACle)

21. september 2026 opdateret af: Nantes University Hospital

Physiopathology of Behavioral Addictions and Biomarkers: microRNAs Implication - MiRACle : a Pilot Study.

The goal of this observational study is to evaluate the expression of miR-10a-5p in the blood in patients with sexual addiction or food addiction. The main question it aims to answer is : To determine whether adults patients with SA or FA exhibit a distinct blood miR-10a-5p expression profile compared with matched healthy controls.

For all participants, one blood sample will be collected.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Anslået)

28

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients with food or sexual addiction, compared with age- and sex-matched healthy controls with no current addictive disorder.

Beskrivelse

Inclusion criteria

For patients with FA:

  • Male and females ≥ 18 years old
  • Already in care or newly initiating care
  • Participating to EVALADD cohort
  • Current diagnosis of FA
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

For healthy controls matched to patients with FA:

  • Male and females ≥ 18 years old
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

For patients with SA:

  • Male ≥ 18 years old
  • Already in care or newly initiating care
  • Participating to EVALADD cohort
  • Current diagnosis of SA
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

For healthy controls matched to patients with SA:

  • Male ≥ 18 years old
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

Exclusion Criteria :

For patients with FA:

  • Presence of a current diagnosis of SA
  • Presence of any current addictive disorder (substance [except tobacco] use disorders, gambling disorder, gaming disorder)
  • Presence of any current instable psychiatric disorder (requiring the initiation or adapation of medication)
  • Pregnancy or breastfeeding woman
  • Trusteeship or curatorship
  • Major cognitive impairment
  • Not fluent in French

For patients with SA:

  • Presence of a current diagnosis of FA
  • Presence of any current addictive disorder (substance [except tobacco] use disorders, gambling disorder, gaming disorder)
  • Presence of any current instable psychiatric disorder (requiring the initiation or adapation of medication)
  • Trusteeship or curatorship
  • Major cognitive impairment
  • Not fluent in French

For healthy controls:

  • Without a current diagnosis of FA
  • Without a current diagnosis of SA
  • Presence of any current addictive disorder (substance [except tobacco] use disorders, gambling disorder, gaming disorder)
  • Presence of any current instable psychiatric disorder (requiring the initiation or adapation of medication)
  • Pregnancy or breastfeeding woman
  • Trusteeship or curatorship
  • Major cognitive impairment
  • Not fluent in French

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Patients with addiction

Patients with food addiction (FA) or sexual addiction

One blood sample wiil be collected into a 10mL K2EDTA BD Vacutainer® tube

Healthy controls

Healthy controls matched on sex and age to patients with food addiction or sexual addiction

One blood sample wiil be collected into a 10mL K2EDTA BD Vacutainer® tube

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blood miR-10a-5p expression
Tidsramme: 3 months

The concentration of each miR-enriched fraction will be determined by spectrophotometric between patients with SA or FA and matched healthy controls.

3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blood additional circulating miRs expression
Tidsramme: 3 months

The concentration of circulating miRs fraction will be determined by spectrophotometric between patients with SA or FA and matched healthy controls.

3 months
Clinical Characteristics
Tidsramme: 3 months

Association between blood expression levels of circulating miRs and age

3 months
Clinical Characteristics
Tidsramme: 3 months

Association between blood expression levels of circulating miRs and sex

3 months
Clinical Characteristics
Tidsramme: 3 months

Association between blood expression levels of circulating miRs and duration of addiction

3 months
Clinical Characteristics
Tidsramme: 3 months

Association between blood expression levels of circulating miRs and severity of addiction

3 months
Clinical Characteristics
Tidsramme: 3 months

Association between blood expression levels of circulating miRs and tobacco-use

3 months
Clinical Characteristics
Tidsramme: 3 months

Association between blood expression levels of circulating miRs and psychiatric disorders

3 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. oktober 2026

Primær færdiggørelse (Anslået)

31. marts 2028

Studieafslutning (Anslået)

30. juni 2028

Datoer for studieregistrering

Først indsendt

15. september 2026

Først indsendt, der opfyldte QC-kriterier

15. september 2026

Først opslået (Faktiske)

21. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • RC26_0091

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .